Clinical Trial

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Study acronym: AURORA-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-15
notable Trial sites expanded: 0 -> 136 locations 2026-08-15
Trial Details
NCT Number NCT07743450
Lead Sponsor Ascletis Pharma (China) Co., Limited
Conditions Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
Enrollment 1,560 participants
Start Date 2026-08
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-14